{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:43:38Z","timestamp":1789688618314,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.yebeh.2019.05.046","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T13:18:51Z","timestamp":1561468731000},"page":"187-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Cognitive profile in BECTS treated with levetiracetam: A 2-year follow-up"],"prefix":"10.1016","volume":"97","author":[{"given":"Francesca Felicia","family":"Operto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia Maria Giovanna","family":"Pastorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Roccella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carotenuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Margari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Verrotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2019.05.046_bb0005","series-title":"Principles and practice of lifespan developmental neuropsychology","first-page":"359","article-title":"Pediatric aspects of epilepsy","author":"Felix","year":"2010"},{"issue":"Suppl. 4","key":"10.1016\/j.yebeh.2019.05.046_bb0010","first-page":"S32","article-title":"Benign epilepsy of childhood with centrotemporal spikes","volume":"39","author":"Wirrell","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0015","first-page":"389","article-title":"Proposal for revised classification of epilepsies and epileptic syndromes","author":"Commission on Classification and Terminology of the International League Against Epilepsy","year":"1989","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0020","series-title":"Epileptic syndromes in infancy, childhood and adolescence","first-page":"203","article-title":"Epilepsy with centro-temporal spikes and related syndromes","author":"DallaBernardina","year":"1995"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.yebeh.2015.01.041","article-title":"Cognitive and behavioral outcomes in benign childhood epilepsy with centrotemporal spikes","volume":"45","author":"Vannest","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0030","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ejpn.2013.01.001","article-title":"Clinical evaluation of language fundamentals in rolandic epilepsy, an assessment with CELF-4","volume":"17","author":"Overvliet","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.yebeh.2018.04.002","article-title":"Language skills in children with benign childhood epilepsy with centrotemporal spikes: a systematic review","volume":"84","author":"Teixeira","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.braindev.2010.10.024","article-title":"Treatment of benign focal epilepsies in children: when and how should be treated?","volume":"33","author":"Oguni","year":"2011","journal-title":"Brain Dev"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0045","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0387-7604(94)90056-6","article-title":"Indication for antiepileptic drug treatment of benign childhood epilepsy with centro-temporal spikes","volume":"16","author":"Hamada","year":"1994","journal-title":"Brain Dev"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0050","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.euroneuro.2015.07.027","article-title":"Adverse cognitive effects of antiepileptic pharmacotherapy: each additional drug matters","volume":"25","author":"Witt","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0055","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1046\/j.1528-1157.2001.41300.x","article-title":"Pharmacokinetic study of levetiracetam in children","volume":"42","author":"Pellock","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0060","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","article-title":"Pharmacokinetic profile of levetiracetam: toward ideal characteristics","volume":"85","author":"Patsalos","year":"2000","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0065","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/phar.1855","article-title":"Efficacy and tolerability of antiepileptic drugs in patients with focal epilepsy: systematic review and network meta-analyses","volume":"36","author":"Campos","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/11316250-000000000-00000","article-title":"Levetiracetam in childhood epilepsy","volume":"12","author":"Verrotti","year":"2010","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0075","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.seizure.2016.01.017","article-title":"The efficacy, tolerability and safety of levetiracetam therapy in a pediatric population","volume":"36","author":"Tekg\u00fcl","year":"2016","journal-title":"Seizure."},{"key":"10.1016\/j.yebeh.2019.05.046_bb0080","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.braindev.2016.09.008","article-title":"Efficacy and tolerability of levetiracetam for pediatric refractory epilepsy","volume":"39","author":"Muramatsu","year":"2017","journal-title":"Brain Dev"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149686","article-title":"Safety of levetiracetam in paediatrics: a systematic review","volume":"11","author":"Egunsola","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0090","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2147\/NDT.S151413","article-title":"A meta-analysis of randomized controlled trials on levetiracetam in the treatment of pediatric patients with epilepsy","volume":"14","author":"Zhang","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0095","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0100","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2147\/NDT.S188111","article-title":"A meta-analysis of levetiracetam for randomized placebo-controlled trials in patients with refractory epilepsy","volume":"15","author":"Chen","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0105","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.seizure.2015.07.004","article-title":"The adverse event profile of levetiracetam: a meta-analysis on children and adults","volume":"31","author":"Verrotti","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/11316250-000000000-00000","article-title":"Levetiracetam in childhood epilepsy","volume":"12","author":"Verrotti","year":"2010","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0115","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.seizure.2014.06.006","article-title":"Evaluation of levetiracetam and valproic acid as low-dose monotherapies for children with typical benign childhood epilepsy with centrotemporal spikes (BECTS)","volume":"23","author":"Xiao","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0120","doi-asserted-by":"crossref","first-page":"e5623","DOI":"10.1097\/MD.0000000000005623","article-title":"Clinical features of benign epilepsy of childhood with centrotemporal spikes in Chinese children","volume":"96","author":"Liu","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0125","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.braindev.2006.09.008","article-title":"Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial","volume":"29","author":"Coppola","year":"2007","journal-title":"Brain Dev"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0130","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.seizure.2006.12.006","article-title":"Levetiracetam monotherapy for children and adolescents with benign rolandic seizures","volume":"16","author":"Verrotti","year":"2007","journal-title":"Seizure."},{"key":"10.1016\/j.yebeh.2019.05.046_bb0135","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.seizure.2018.01.015","article-title":"Effects of levetiracetam and sulthiame on EEG in benign epilepsy with centrotemporal spikes: a randomized controlled trial","volume":"56","author":"Tacke","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0140","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.ejpn.2016.07.015","article-title":"Effect of anticonvulsive treatment on neuropsychological performance in children with BECTS","volume":"20","author":"Tacke","year":"2016","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0145","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.yebeh.2009.08.026","article-title":"Clinical efficacy and cognitive and neuropsychological effects of levetiracetam in epilepsy: an open-label multicenter study","volume":"16","author":"Wu","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0150","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.yebeh.2007.07.011","article-title":"A pilot study transitioning children onto levetiracetam monotherapy to improve language dysfunction associated with benign rolandic epilepsy","volume":"11","author":"Kossoff","year":"2007","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0155","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.spen.2017.10.011","article-title":"Cognitive and behavioral comorbidities: an unwanted effect of antiepileptic drugs in children","volume":"24","author":"Ulate-Campos","year":"2017","journal-title":"Semin Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0160","series-title":"Administration and scoring manual","article-title":"WISC-IV. Wechsler Intelligence Scale for Children","author":"Wechsler","year":"2003"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0165","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.braindev.2017.01.006","article-title":"Cognitive and behavioral effects of new antiepileptic drugs in pediatric epilepsy","volume":"39","author":"Moavero","year":"2017","journal-title":"Brain Dev"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0170","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/1817-1745.139282","article-title":"Neuropsychological implications of adjunctive levetiracetam in childhood epilepsy","volume":"9","author":"Posar","year":"2014","journal-title":"J Pediatr Neurosci"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0175","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/j.1528-1167.2009.02197.x","article-title":"Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial","volume":"50","author":"Levisohn","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0180","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/0883073811417183","article-title":"A long-term open-label extension study assessing cognition and behavior, tolerability, safety, and efficacy of adjunctive levetiracetam in children aged 4 to 16 years with partial-onset seizures","volume":"27","author":"Schiemann-Delgado","year":"2012","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0185","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.eplepsyres.2005.10.006","article-title":"Levetiracetam: an improvement of attention and of oral fluency in patients with partial epilepsy","volume":"68","author":"Piazzini","year":"2006","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0190","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.yebeh.2008.07.012","article-title":"The effects of levetiracetam on cognition: a non-interventional surveillance study","volume":"13","author":"Helmstaedter","year":"2008","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0195","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.yebeh.2010.02.011","article-title":"Cognitive outcome of antiepileptic treatment with levetiracetam versus carbamazepine monotherapy: a non-interventional surveillance trial","volume":"18","author":"Helmstaedter","year":"2010","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0200","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.clinph.2011.09.012","article-title":"Effect of levetiracetam monotherapy on background EEG activity and cognition in drug-na\u00efve epilepsy patients","volume":"123","author":"Cho","year":"2012","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.yebeh.2019.05.046_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/NDT.S181886","article-title":"Levetiracetam for epilepsy: an evidence map of efficacy, safety and economic profiles","volume":"15","author":"Yi","year":"2018","journal-title":"Neuropsychiatr Dis Treat"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550501930397X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550501930397X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:27:52Z","timestamp":1761503272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152550501930397X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":41,"alternative-id":["S152550501930397X"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.05.046","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cognitive profile in BECTS treated with levetiracetam: A 2-year follow-up","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.05.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}